Form 4: Ironwood Pharmaceuticals CEO Thomas McCourt Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Ironwood Pharmaceuticals CEO Thomas McCourt sold shares to cover tax withholding obligations related to the vesting of restricted stock units and performance-based restricted stock units.
Summary
- On February 10, 2025, Thomas A. McCourt, CEO of Ironwood Pharmaceuticals, sold 139,064 shares of Class A Common Stock at a price of $1.76 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units and performance-based restricted stock units.
- Following the transaction, McCourt directly owns 1,160,634 shares of Ironwood Pharmaceuticals.
- McCourt has granted power of attorney to several individuals to execute filings on his behalf.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (share sale for tax obligations) and grants power of attorney, which are neutral events.
Industry Context
Sales of shares to cover tax obligations are a routine occurrence for executives who receive equity compensation. This transaction is unlikely to have a significant impact on the company's operations or stock price.
Stakeholder Impact
- The share sale may have a minor dilutive effect on existing shareholders, but the impact is likely insignificant.
Key Dates
| Date | Description |
|---|---|
| 2025-02-07 | Date of Power of Attorney execution |
| 2025-02-10 | Date of share sale transaction |
| 2025-02-12 | Date of Form 4 filing |
Keywords
Form 4, Ironwood Pharmaceuticals, Thomas McCourt, Share Sale, Tax Obligations, IRWD, CEO, Power of Attorney, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.